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Inﬂammation plays an important role in the pathogenesis of endometriosis. Inﬁltration of peritoneal
macrophages and local proinﬂammatory mediators in the peritoneal microenvironment affect ovarian
function and pelvic anatomy leading to the symptoms and signs of endometriosis. The identiﬁcation of a
noninvasive marker for endometriosis will facilitate early diagnosis and treatment of this disease. This
review provides an overview of local microenvironmental inﬂammation and systemic inﬂammation
biomarkers in endometriosis.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Endometriosis is considered a chronic inﬂammatory disease. It
is deﬁned as the presence of endometrial stroma and glands
outside the uterine cavity. The prevalence of endometriosis in
women of reproductive age is about 10%.1 Although the exact eti-
ology of endometriosis is still controversial, Sampson's retrograde
menstruation theory is a widely accepted explanation for endo-
metriosis.2 In order to ectopically implant on the peritoneal cavity,
reﬂuxed endometrial tissue processes through attachment, acute
inﬂammation, macrophage inﬁltration, tissue remodeling, and
neovascularization. Inﬂammation can lead to an anatomic disorder
and affect ovarian function, which plays an important role in the
pathogenesis of endometriosis. Inﬁltration of peritoneal macro-
phages and local proinﬂammatory mediators in the peritoneal
microenvironment affect the symptoms and signs of women with
endometriosis. This review provides an overview of local micro-
environmental inﬂammation and systemic inﬂammation bio-
markers in endometriosis.s of interest.
, National Cheng Kung Uni-
701, Taiwan.
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for Gynecologic Endoscopy and MinimLocal microenvironment inﬂammation in endometriosis
Endometriosis is a pelvic inﬂammatory process with altered
immune surveillance in the local peritoneal microenvironment. The
endometriosis-associated inﬂammatory responses are dependent
on increased activated macrophages and their secreted cytokines in
peritoneal ﬂuid. A local inﬂammatory microenvironment will sus-
tain the growth and maintenance of endometriosis through
endometrial-peritoneal adhesion, invasion, angiogenesis, and pro-
liferation. The inﬂammation process in endometriosis further causes
pelvic pain and infertility, two major symptoms of endometriosis.Cyclooxygenase-2 in endometriosis
Local proinﬂammatory mediators, such as interleukin (IL)-1b
and tumor necrosis factor (TNF)-a, will activate nuclear factor kB
(NF-kB) and hypoxia inducible factor (HIF)-1a signaling pathways,
and then increase cyclooxygenase (COX)-2 expression in endome-
triosis.3 These cytokines act as autocrine and/or paracrine signals to
regulate local immune and inﬂammatory responses. COX is a rate-
limiting enzyme in the biosynthesis of proinﬂammatory prosta-
glandins (PGs). COX-1 is constitutively expressed, and its primary
function is housekeeping. COX-2 is an inducible enzyme which is
usually absent under physiologic conditions, but rapidly expressed
after stimulation by cytokines and proinﬂammatory agents in
various pathological conditions such as endometriosis.4,5ally Invasive Therapy. Published by Elsevier Taiwan LLC. All rights reserved.
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increased in women with endometriosis, whereas expression of
COX-1 was only increased in severe stages of endometriosis.4 The
expression of COX-2 in peritoneal macrophages is associated with
PG levels in peritoneal ﬂuid and the severity of endometriosis.
Treatment with IL-1b, TNF-a, or PGE2 induced a signiﬁcant increase
of COX-2 expression in peritoneal macrophages in disease-free
women. However, these proinﬂammatory agents failed to induce
COX expression in peritoneal macrophages in women with endo-
metriosis. Since distinct patterns of COX-2 expression in peritoneal
macrophages were found under the exposure of microenviron-
mental stimulants in peritoneal ﬂuid, the failure of proin-
ﬂammatory factors to stimulate COX-2 expression in peritoneal
macrophages from women with endometriosis may be due to the
desensitization of active macrophages (expressed CD25 cell anti-
gen) under long-term stimulation in peritoneal ﬂuid.
COX-2 is overexpressed in glandular epithelia and stroma of
ectopic endometriotic implants.5,6 In addition, increased COX-2
expression is found in eutopic endometria cells from women with
endometriosis compared with disease-free women. Increased COX-
2 and COX-2-derived PGE2 production regulate cell survival,
migration, and invasion of ectopic endometriotic tissues.6 The
proinﬂammatory cytokines in the peritoneal microenvironment
will stimulate the implantation of ectopic endometriotic tissues.
Elevation of COX-2 expression in normal and endometriotic stromal
cells is regulated by proinﬂammatory cytokines such as IL-1b5 or
PGE2 itself (in an autocrine manner),7 primarily due to increased
COX-2 mRNA stability. In ectopic endometriotic stromal cells, IL-1b
not only increases mRNA stability but also upregulates COX-2
promoter activity (transcriptional regulation), which is mediated
via mitogen-activated protein kinase (MAPK)-dependent signaling
pathways through binding to the cAMP-responding element site of
a COX-2 promoter. Downregulation of microRNAs (miR199a and
miR16) also lead to increased COX-2 translation.3 In addition,
chicken ovalbumin upstream promoter-transcription factor II
(COUP-TFII) regulates a subset of genes involved in endometrial
stroma cell decidualization and plays a role in controlling the
expression of inﬂammatory cytokines. Downregulation of COUP-
TFII in endometriotic stromal cells mediated by proinﬂammatory
cytokines including IL-1b, TNF-a, and transforming growth factor
(TGF)-b1 via microRNA-302a results in COX-2 upregulation.8 These
promote an inﬂammatory microenvironment for the development
of endometriosis.
Endometriosis is also considered as an estrogen-dependent in-
ﬂammatory disease.7 Inﬂammation and estrogen are lined in a
positive feedback cycle which enhances the expression of aroma-
tase, COX-2, and local estrogen production in ectopic endometriotic
lesions. Estrogen receptor b (ERb) in endometriotic tissue is
increased and mediates the induction of COX-2 expression by
estradiol.7 A lack of ERb promoter methylation is associated with
increased ERb activity in endometriotic stromal cells, and hyper-
methylation of a CpG island at the promoter region silences ERb
gene expression in eutopic endometrial stromal cells. Increased
ERb in endometriotic stromal cells suppressed the expressions of
ERa and progesterone receptors, leading to inﬂammation, proges-
terone resistance, and deﬁcient inactivation of estradiol in endo-
metriotic tissue. Similar epigenetic changes in endometriotic tissue
are found in the orphan nuclear receptor steroidogenic factor (SF) 1,
which mediates PGE2-dependent induction of estradiol produc-
tion.7 In the MCF-7 human mammary adenocarcinoma cell line,
hypoxic treatment induces activation of HIF-1a and upregulates
inﬂammatory response genes such as COX2 expression.9 In our
recent study,10 treatment of endometrial stromal cells with hypoxia
induced ERb expression. By contrast, knockdown of HIF-1a abol-
ished hypoxia-induced ERb expression and increased ERaexpression.10 It further provides important information regarding
how hypoxia mediates estrogen action via different ER expressions
which may induce inﬂammatory responses in endometriosis.
Prostaglandins in endometriosis
Elevated PGE2 and PGF2a in peritoneal ﬂuid due to the over-
expression of COX-2 may contribute to the presence of symptoms
of endometriosis such as dysmenorrhea and infertility.4 PGE2 is a
polypotent eicosanoid that regulates many pathophysiological
processes in the development of endometriosis, including cell
proliferation, antiapoptosis, immune suppression, and angiogen-
esis.11 Due to its inherent nature, although PGE2 production is
higher in epithelial cells than in the stromal cells of endometriotic
tissues, endometriotic stromal cells have more potential to migrate
and invade than epithelial cells.6 Several proinﬂammatory cyto-
kines induce COX-2 expression in peritoneal macrophages and
endometriotic stromal cells, leading to increased PGE2 level in
peritoneal ﬂuid. However, the short half-lives of COX-2 and PGs
cannot explain their continuous overexpression in both peritoneal
macrophages and ectopic endometriotic stromal cells from patients
with endometriosis. Two positive feedback loops, COX-2-PGE2-es-
trogen in ectopic endometriotic stromal cells and COX-2-PGE2-pro-
inﬂammatory cytokines such as IL-1b, TNF-a, and even PGE2
secreted by peritoneal macrophages will constantly keep an
elevated PGE2 concentration in the peritoneal ﬂuid of patients with
endometriosis as a self-supported survival system to the growth of
endometriosis.11,12
Endometriosis is an estrogen-dependent disease. Two
committed steps required for de novo synthesis of estrogen are
steroidogenic acute regulatory protein (StAR) and aromatase. PGE2-
induced StAR expression, which transports cholesterol across the
mitochondrial membrane to the inner mitochondrial leaﬂet, is
restricted in ectopic endometriotic stromal cells.13e15 Similar to the
mechanism seen in StAR regulation, the induction of aromatase
expression by PGE2 occurs only in ectopic endometriotic stromal
cells, and is mediated via binding to EP2/EP4 receptor-coupled
signaling pathways.16 Therefore, selective inhibition of EP2/EP4
receptors is considered as potential nonsteroidal therapy for
women with endometriosis in human endometriotic cells.17
Furthermore, estrogen per se is not a mitogen. The mitogenic
effect of estrogen is mediated by the upregulation of ﬁbroblast
growth factor (FGF)-9.18 FGF-9 is an endometrial stromal growth
factor which binds to its high-afﬁnity receptor, especially FGFR2IIIC,
which activates Ras-Raf-MEK-ERK and phospholipase C-calcium-
mTOR pathways.19,20 The induction of FGF-9 expression by PGE2 to
induce endometriotic cell proliferation is biphasic via binding to
different EP receptors. PGE2-induced FGF-9 expression and estro-
gen biosynthesis via the EP2 receptor coupled PKA signaling
pathway is a delayed response to PGE2 (after 24 hours). Only in
ectopic endometriotic stromal cells, the induction of FGF-9
expression by PGE2 is mediated via the EP3 receptor-activated
PKCs signaling pathway in an estrogen-independent manner.21
This upregulation of FGF-9 via the EP3 receptor signaling
pathway through Gq-protein activation is the acute response to
PGE2 (within 12 hours). It activates the downstream signaling
cascade to phosphorylate the transcription factor Elk-1, then binds
to the FGF-9 promoter and initiates its transcription.
Immune dysfunction such as hyperactive peritoneal macro-
phage with poor phagocytic ability is considered as an important
factor in the development of endometriosis. The phagocytic ca-
pacity of peritoneal macrophages is mediated by at least two
mechanisms. The ﬁrst mechanism is the secretion and activation of
matrix metalloproteinases (MMPs) to break down the extracellular
matrix, and the second is the expression of scavenger receptors on
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debris. Decreased expression and the enzymatic activity of MMP-9
by peritoneal macrophages were seen in women with endometri-
osis, which failed to destroy the basement membrane and break
down endometriotic tissues.22 The suppression of peritoneal
macrophageMMP-9 expressionwas demonstrated after incubation
by the peritoneal ﬂuid derived from cells of women with endo-
metriosis. PGE2, elevated in the peritoneal ﬂuid of women with
endometriosis, effectively decreased peritoneal macrophage MMP-
9 expression via the EP2/EP4 receptor-dependent PKA signaling
pathway.
Reduced scavenger receptor expression also results in decreased
macrophage phagocytic function. The known scavenger receptors
participating in the macrophage phagocytosis include Class A and
Class B scavenger receptors. The SR-BIII (known as CD36) expres-
sion and phagocytic ability were reduced in peritoneal macro-
phages derived from women with endometriosis compared with
cells from disease-free women.23 PGE2 inhibited CD36-dependent
phagocytosis of peritoneal macrophages via the EP2 receptor-
dependent signaling pathway.24 Ectopic expression of CD36
rescued the PGE2-inhibited phagocytic ability of peritoneal mac-
rophages. In an animal study, this inhibiting effect increased the
number and size of endometriotic lesions in vivo. Similar expres-
sions in the levels of annexin A2 in peritoneal macrophages were
found in endometriosis.25 Therefore, PGE2-downregulated annexin
A2, MMP-9, and CD36 expressions, which impairs the ﬁrst and
second mechanisms of phagocytic capability of macrophages, fa-
cilitates the survival of ectopic endometriotic tissues. Inhibiting
PGE2 signaling may help to develop novel strategies against
endometriosis.
Leptin in endometriosis
Leptin is a multifunctional hormone with immunoregulatory,
proinﬂammatory, and angiogenic effects and plays an important
role in controlling reproductive functions and the development of
endometriosis. Leptin is a prognostic factor of ovarian responsive-
ness after hyperstimulation. Elevated leptin concentrations may
modulate embryo quality and be associated with poor outcome of
in vitro fertilization/intracytoplasmic sperm injection cycle.26 In our
previous study,27 there was a negative correlation between follic-
ular ﬂuid leptin and the ﬂow index of ovarian stroma in the control
group. Although there were nonsigniﬁcant increased serum leptin
values in the endometriosis group, loss of the above correlationwas
found in women after laparoscopic ovarian cystectomy for
endometriomas.
Leptin modulates inﬂammatory processes and immune re-
sponses.28 Endometriosis is considered as a good example of a
chronic inﬂammatory disease. Although direct association of leptin
with pelvic inﬂammation and local immune response has not so far
been elucidated, leptin may modulate the functions of peritoneal
macrophages and aberrant gene expression of stromal cells, which
might contribute to the pathophysiological process of endometri-
osis. Leptin mRNA was undetectable or was present in only a
minute amount in eutopic endometrium.29 By contrast, there was a
marked increase in leptin mRNA and protein expression in ectopic
endometriotic lesions of patients with endometriosis. The leptin
receptor mRNA levels were suppressed, and were associated with
the severity of endometriosis. Administration of leptin stimulated
its ownmRNA expression in ectopic endometriotic stromal cells but
decreased leptin receptor mRNA expression. In addition, leptin
signiﬁcantly enhanced both eutopic and ectopic endometrial stro-
mal cell proliferation. Hypoxic stress is associated with the growth
and survival of endometriotic lesions. We also found the mRNA and
protein levels of HIF-1a, a master transcription factor that mediatesthe hypoxic effect, were greater in ectopic endometriotic tissue.30
HIF-1a could bind to a leptin promoter and then induce its activ-
ity after hypoxia treatment. Therefore, our data demonstrate that
aberrant expression of leptin in ectopic endometriotic stromal cells
is induced, at least in part, by elevated level of HIF-1a in these cells,
and the mitogenic and auto-augmentation effects of leptin may
contribute to the pathogenesis of endometriosis.
Leptin is a cytokine which promotes CD4þ T helper I cell pro-
liferation, macrophage phagocytosis, and the secretion of inﬂam-
matory cytokines.28 Concentration of peritoneal ﬂuid leptin was
found to be increased in patients with endometriosis.31 Increased
peritoneal ﬂuid leptin in endometriosis patients may affect local
inﬂammatory/immune reactions.32 Peritoneal ﬂuid leptin showed a
negative correlation with IL-1b, a classical inﬂammatory cytokine,
and interferon-gamma, a major T helper cell type I cytokine. It also
showed the existence of a positive correlation with the percentage
of CD3þ pan-T cells and inﬁltration of CD4þ T helper cells. Elevated
leptin levels in peritoneal ﬂuid may contribute to the pathological
process of endometriosis through the activation of peritoneal
macrophages. In our study, treatment of peritoneal macrophages
with leptin induced COX-2 expression.31 Increased production of
PGF2a by peritoneal macrophages was found after leptin stimula-
tion in women with endometriosis. It affects the presence of
symptoms, such as menstrual pain, of patients with endometriosis.
These lines of evidence support that peritoneal ﬂuid leptin may
play a role in endometriosis-associated chronic pelvic pain, but is
not involved in the pathophysiology of endometriosis-associated
infertility.33NF-kB in endometriosis
NF-kB, a proinﬂammatory transcription factor, plays an impor-
tant role in both physiological immunity and pathological inﬂam-
mation. Peritoneal oxidative stress, secondary to iron overload in
the peritoneal cavity during retrograde menstruation, may impair
cellular function by increasing proinﬂammatory gene expression
through the regulation of NF-kB activation.34 The activation of NF-
kB involves macrophage migration inhibitory factor (MIF) gene
expression in ectopic endometrial cells in response to IL-1b.35
Therefore, various inﬂammatory factors activate NF-kB, and NF-
kB further stimulates the synthesis of proinﬂammatory cytokines to
form an autoregulatory loop. Constitutive activation of NF-kB,
involving p65- and p50-containing dimmers, in endometriotic le-
sions and peritoneal macrophages from patients with endometri-
osis promotes inﬂammation, invasion, angiogenesis, and cell
proliferation, and inhibits apoptosis of endometriotic cells.36 The
suppressed progesterone receptor (PR) and increased COX-2 levels
is contributed to progesterone resistance and inﬂammation. PR-A
and PR-B in the uterus play an anti-inﬂammatory role that antag-
onizes NF-kB activation and COX-2 expression.37 PR levels, partic-
ularly the PR-B isoform, are signiﬁcantly decreased in
endometriotic stromal cells, which is associated with a high ERb-
to-ERa ratio.38 This aberrant increased ERb-to-ERa ratio in endo-
metriotic stromal cells is also regulated by hypoxia,10 which may be
associated with elevated NF-kB activation. Hypoxia-induced HIF-1a
expression is blocked by NF-kB inhibition under hypoxic conditions
at the translational level in cancer cells.39 The alteration of physi-
ologic cyclic NF-kB-p65 subunit activation pattern in women with
endometriosis is concurrent with progesterone resistance that
could affect the implantationwindowand lead to infertility.40 Some
drugs with NF-kB inhibitory properties are effective in suppressing
the above endometriosis-associated changes and reduce the
expression of COX-2, which is a promising therapeutic potential for
endometriosis.41
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endometriosis
The levels of cytokines and chemokines, such as IL-1b, TNF-a, IL-
6, and IL-8 secreted by peritoneal macrophages and ectopic endo-
metriotic lesions were abnormally increased in peritoneal ﬂuid.42
These elevated peritoneal factors induce COX-2 expression and
trigger PGE2 production, which forms a positive feedback loop to
enhance the development of endometriosis. IL-1b is a major
proinﬂammatory cytokine that is overproduced by endometriosis-
derived peritoneal macrophages and is elevated in the peritoneal
ﬂuid of patients with endometriosis. As we have discussed in the
previous sections, although IL-1b failed to induce COX-2 expression
in peritoneal macrophages from women with endometriosis, IL-1b
enhances signiﬁcant COX-2 expression in peritoneal macrophages
from disease-free women, and eutopic and ectopic endometrial
stromal cells.4,5 Especially, IL-1b upregulates both COX-2 mRNA
stability and promoter activity in ectopic endometriotic stromal
cells. Similarly, IL-1b-induced COX-2 expression upregulates cell
migration and the invasion ability of endometrioma-derived
ectopic endometrial mesenchymal stem cells.43
TNF-a mediates inﬂammation by inducing inﬂammatory me-
diators IL-6, IL-8, granulocyte macrophageecolony-stimulating
factor, and monocyte chemoattractant protein (MCP)-1 secretion in
the endometrium.44 TNF-a can enhance endometrial epithelial cell
proliferation in the ectopic environment of women with endome-
triosis. TNF-a-induced COX-2 overexpression in the eutopic endo-
metrium of women with endometriosis is through NF-kB
activation, which may play a critical role in the pathophysiology of
endometriosis formation.45 Prolonged stimulation with TNF-a will
induce partial methylation in the promoter region of PR-B with
concomitant reduction of PR-B expression in immortalized
epithelial-like endometriotic cells that is contributed to proges-
terone resistance.46
TGF-b may be involved in the initiation of menstruation via
vasoconstriction, scarless postmenstrual regeneration of endome-
trium, and establishment and/or maintenance of endometriosis.47
The levels of TGF-b, secreted by the endometrial cells and macro-
phages, are increased in the peritoneal ﬂuid of endometriosis. TGF-
b signiﬁcantly induces the expression of macrophage colony-
stimulating factor receptor encoded by the c-fms gene and en-
hances endometrial epithelial cell transmesothelial invasion.48
However, until now, more studies regarding TGF-b in the patho-
genesis of endometriosis are needed.
The activation of protease-activated receptor 2 (PAR2), as an
important mediator of inﬂammation activated by enzymes from
neutrophils and mast cells, stimulates proliferation and IL-6 and IL-
8 secretion of endometriotic stromal cells through the involvement
of MAPKs.49 IL-6 expression is highly associated with angiogenesis
and migration. Inﬂammatory stimuli, IL-1b and TNF-a, ﬁrst induce
activin-A protein expression in endometrioma stromal cells. It
further increases the expression of IL-6 and PAR-2 mRNA expres-
sion, and enhances the proliferation of endometrioma stromal
cells.50 Additionally, TGF-b1 directly increases the expression of
PAR-2 and increases IL-6 secretion in endometriotic stromal cells.51
IL-8 induces chemotaxis of neutrophils and is also a potent angio-
genic agent. IL-8 may act as an autocrine growth factor in the
endometrium promoting the vicious circle of endometrial cell
attachment, cell growth, and further self-stimulation in the path-
ogenesis of endometriosis.52 In contrast to higher levels of leptin in
early stages of endometriosis, elevated peritoneal ﬂuid IL-8 levels in
women with endometriosis is correlated with the severity of the
disease.53 Sex steroids stimulate the chemokine IL-8 expression in
endometrial endothelial cells from women with endometriosis.54
IL-8 increases endometrial stromal cell metalloproteinase activityand invasive capability that degrade extracellular matrix to help the
endometrial cells invade the peritoneum and to develop an endo-
metriotic lesion.55
Macrophage-derived factors, such as migration inhibitory factor
(MIF) and MCP-1, can promote angiogenesis in the development of
endometriosis.56 MIF, with its potent proinﬂammatory and angio-
genic properties, is markedly elevated in lesions from the early
stage of endometriosis, particularly in endometrial implants with
highly vascularized, active forms of the disease.57 The over-
production of IL-1b in endometriosis upregulates the expression of
MIF in endometrial stromal cells and ectopic endometrial cells via
NF-kB nuclear translocation that shows the immunomodulatory
properties of MIF in endometriosis-associated inﬂammation,
ectopic cell growth, angiogenesis, and tissue remodeling.35,58 MIF
acts directly on ectopic endometrial cells to stimulate the synthesis
of COX-2 and the production of PGE2 that triggers the coordinate
activation of multiple enzymes in the PGE2 biosynthesis pathway.59
MIF, interacting with ectopic endometrial cells, further markedly
upregulates the secretion of major angiogenic factors including
vascular endothelial growth factor (VEGF), IL-8, and MCP-1
expression via CD44, CD74, and MAPK signaling pathways.60
The peritoneal ﬂuid level of MCP-1 is positively correlated with
leptin level, especially in the early stages of endometriosis, which
may play a role in the pathogenesis of endometriosis-associated
infertility.61 The levels of VEGF are signiﬁcantly increased in the
endometrial stromal cells of women with endometriosis in the
presence of MCP-1 chemokine and/or estradiol.62 In addition, the
stimulation of MCP-1 expression by sex hormones in the endo-
metrial endothelial cells inwomenwith endometriosis may involve
recruiting mononuclear cells and contributing to the inﬂammatory
aspect of endometriosis.63
Systemic inﬂammation biomarkers in endometriosis
Endometriosis may be asymptomatic or associated with
nonspeciﬁc symptoms. This causes delays in the early diagnosis and
treatment time of endometriosis by about 8e12 years.64 Conven-
tional laparoscopic surgery, even mini-laparoscopic surgical tech-
nique, is indicated for womenwith endometriosis because it is less
invasive and causes less postoperative pain.65,66 Although lapa-
roscopy is the gold choice for the deﬁnitive diagnosis of endome-
triosis, noninvasive methods are needed for preoperative and
follow-up evaluation. Ultrasound is an adequate noninvasive
approach to detect ovarian endometrioma,67 but is hard to rule out
peritoneal endometriosis and adhesion. A reliable single biomarker
or panel of biomarkers may help to diagnose endometriosis earlier
and reduce unnecessary operation.68 However, to date, it still
cannot identify suitable peripheral biomarkers for clinical use.69
There are different kinds of peripheral biomarkers, including
cytokines, antibodies, cell populations, glycoproteins, cell adhesion,
growth factors, proteomics, hormones, angiogenesis, and apoptosis,
proposed for clinical use in the diagnosis of endometriosis. There
has been various conﬂicting differences among these studies. These
conﬂicting results may be due to patient numbers, the phase of
menstrual cycle, the type of endometriosis, and selection of an
appropriate control group.69 For example, our cytokine study found
elevated levels of IL-4 in the serum of women with endometriosis,
and those were reduced to normal after medical and surgical
treatment.70 This suggests that altered cytokine secretion of T-
helper cell type 1 and 2 plays a role in immunologic responses to
endometriosis. But another study showed no changes in serum IL-
2, IL-4, or IL-10 levels.71 Conﬂicting results were also found in
biomarkers of cell adhesion, which is important in cellecell inter-
action. Our previous study showed signiﬁcantly elevated serum
levels of soluble intercellular adhesion molecule-1 in women with
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ence.73 Furthermore, leptin plays a role in inﬂammatory processes
and immune responses.28 Leptin links proinﬂammatory T helper 1
immune responses, and induces the expression of intercellular
adhesion molecule 1 and matrix metalloproteinases. Matarese
et al74 found that serum and peritoneal ﬂuid leptin levels were
signiﬁcantly increased in patients with endometriosis. However,
our study showed elevated leptin concentrations in peritoneal ﬂuid
of endometriosis,31 but without signiﬁcant change in serum
levels.27
The most commonly used biomarker for the detection of
endometriosis is cancer antigen CA125, which is elevated in the
serum of patients with endometriosis but lacks sensitivity and
speciﬁcity. It is necessary to pay attention to the elevated ﬂuctua-
tions in CA125 during menstruation to prevent unnecessary diag-
nostic procedures on unaffected women with a similar
presentation as women with endometriosis.75 Serum CA125 test
alone may be beneﬁcial in diagnosing advanced stages of endo-
metriosis and in monitoring treatment.76,77 Preoperative CA125
levels higher than 65 IU/mL helps to decide preoperative bowel
preparation for patients with a high risk of severe pelvic adhesion,
with a sensitivity of 76%, a speciﬁcity of 71%, a positive predictive
value of 76%, and a negative predictive value of 93.2%.78 In addition,
a panel of biomarkers may be more reliable with increased sensi-
tivity and speciﬁcity in the screening for endometriosis.68 Mihalyi
et al79 reported that a panel of six selected biomarkers (plasma
concentrations of IL-6, IL-8, TNF-a, high-sensitivity C-reactive
protein, and cancer antigens CA125 and CA19-9) during the
secretory phase or during menstruation can diagnose both
minimal-mild and moderate-severe endometriosis with high
sensitivity and clinically acceptable speciﬁcity.79 The other serum
biomarker combination of MCP-1, MIF, leptin, and CA-125
improved the diagnostic capability to 73% of patients, with 94%
overall accuracy.80,81
Recently, microRNAs appear to be potent regulators of gene
expression at the post-transcriptional level in the development of
endometriosis, including those associated with hypoxia, inﬂam-
mation, proliferation, angiogenesis, apoptosis, and extracellular
matrix remodeling.3 Endometriosis-associated microRNAs may be
secreted from tissues into the bloodstream and be identiﬁed in the
serum. Thus, they may be attractive candidates of novel diagnostic
biomarkers for endometriosis. For example, in our recent study,
elevation of miR20a in endometriotic stromal cells is secondary to
HIF-1a-dependent transcriptional upregulation.82 It induces the
expression of several MAPK-regulated angiogenic genes and en-
hances PGE2-induced FGF-9 expression. Thus, miR20a may be an
important modulator in the development of endometriosis and can
be considered as a potential biomarker for the diagnosis of endo-
metriosis. The use of technologies, including genomics, proteomics,
and metabolomics, in the future may help to identify potential
novel biomarkers with high sensitivity and speciﬁcity for clinical
use in the differential diagnosis of endometriosis and as a nonin-
vasive diagnostic test to shorten the period between onset of
symptoms and diagnosis of endometriosis.
Conclusion
Inﬂammatory factors play an important role in the pathophys-
iology of endometriosis, whichwill interact locally and systemically
to affect symptoms and may be biomarkers for diagnosis or the
target of treatment. Although treatment with COX inhibitors can
improve the symptoms and signs of women with endometriosis,
short half-life and unfavorable side effects affect the compliance of
the treatment. Endometriosis-focused basic research can help to
provide better diagnosis, treatment, and a way of prevention.However, there is disappointment with the slow progress of these
developments associated with the opaqueness of clinical endo-
metriosis trials.83 Further studies are needed to clarify the potential
mechanism of inﬂammation in the development of endometriosis
and to develop a suitable preventive or therapeutic strategy for this
disease.
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